Booming Clinical Research Business Could Trigger Regulatory Overhaul In India
This article was originally published in PharmAsia News
Executive Summary
SAN FRANCISCO - Foreign companies could soon get the go-ahead to conduct Phase I studies in India, as part of a national regulatory overhaul spurred on by booming clinical research business, regional experts say
You may also be interested in...
Wyeth Defends Clinical Trial Standards After Indian Baby’s Death
NEW DELHI - Wyeth has defended its "high-quality" clinical patient trial standards after India's drug quality regulator ordered a review of trials for an advanced pneumonia vaccine by the Indian unit of the U.S. pharmaceutical giant following the death of a baby
Wyeth Defends Clinical Trial Standards After Indian Baby’s Death
NEW DELHI - Wyeth has defended its "high-quality" clinical patient trial standards after India's drug quality regulator ordered a review of trials for an advanced pneumonia vaccine by the Indian unit of the U.S. pharmaceutical giant following the death of a baby
India May Soon Allow Outside Phase I Drug Studies
Certain studies by multinational drug companies would be allowable under pending changes to India’s clinical trial regulations.